市場調查報告書
商品編碼
1423209
2024-2032 年按類型(肌鈣蛋白、心肌肌酸激酶、肌紅蛋白、腦鈉尿肽或NT-proBNP、缺血修飾白蛋白等)、測試地點、應用和區域分類的心臟生物標記市場報告Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2024-2032 |
2023年,全球心臟生物標記市場規模達到107億美元。展望未來, IMARC Group預計到2032年市場規模將達到210億美元,2024-2032年複合年成長率(CAGR)為7.6%。
心臟標記物,也稱為心臟生物標記物,當心臟受到壓力或肌肉受損時,會釋放到血液中。這些標記物包括不同類型的酵素、荷爾蒙和蛋白質,例如心肌肌鈣蛋白、肌酸激酶 (CK)、缺血修飾白蛋白 (IMA) 和肌紅蛋白。測量和測試這些標記物可以幫助診斷心臟疾病,如心肌缺血和急性冠狀動脈綜合症 (ACS)。目前,用於確定這些病症風險的分類和診斷系統是基於心電圖 (ECG) 和臨床病史。然而,這些系統不足,可能導致誤診或延誤治療。由於心臟標記測試具有更高的準確性,並且可以在發病的早期階段識別病情,因此它們在全球範圍內獲得了廣泛的關注。這些標記還可以幫助更準確地監測這些疾病的預後,並為患者提供最有效的治療。
在過去的幾年中,患有 ACS 的患者數量不斷增加,這在全球範圍內產生了對心臟標記檢測的需求。除此之外,患者和醫療保健提供者對各種心血管疾病早期診斷重要性的認知不斷提高,推動了對這些標記物的需求。此外,還有許多私人和公共組織正在投資研發活動,以開發心臟生物標記領域的先進技術。例如,高敏感性心肌肌鈣蛋白 I 的血液檢測已被證明可以識別二次心臟病發作風險較高的患者。此外,生物標記測試提供的高精度和快速結果,再加上負擔得起的心臟照護端測試的可用性,是促進市場成長的其他一些因素。
The global cardiac biomarkers market size reached US$ 10.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032.
Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.
Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac biomarkers market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on type, location of testing, and application.
Troponins (T and I)
Myocardial Muscle Creatine Kinase (CK-MB)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia Modified Albumin (IMA)
Others
Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.
Laboratory Testing
Point of Care Testing
Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.
North America
Asia Pacific
Europe
Middle East and Africa
Latin America
Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.
The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.